154920-37-3

Basic information

• Product Name: 13-amino-1,4,7,10-tetra(phenylmethyl)-1,4,7,10-tetraazatridecane
• CAS NO: 154920-37-3
• Molecular Weight: 563.83
• Mol File: 154920-37-3.mol

Chemical Properties

• CAS DataBase Reference: 13-amino-1,4,7,10-tetra(phenylmethyl)-1,4,7,10-tetraazatridecane(CAS DataBase Reference)
• NIST Chemistry Reference: 13-amino-1,4,7,10-tetra(phenylmethyl)-1,4,7,10-tetraazatridecane(154920-37-3)
• EPA Substance Registry System: 13-amino-1,4,7,10-tetra(phenylmethyl)-1,4,7,10-tetraazatridecane(154920-37-3)

Safety Data

• Hazardous Substances Data: 154920-37-3(Hazardous Substances Data)

Upstream product

• 154920-45-3 9,12,15,18-tetra(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9,12,15,18-pentaazaoctadecane 
• 90914-08-2 N-[N-(tert-Butyloxycarbonyl)-3-aminopropyl]benzylamine 
• 100-52-7 benzaldehyde 
• 13910-48-0 N-benzyl-1,3-diaminopropane 
• 154920-48-6 {3-[(2-Amino-ethyl)-benzyl-amino]-propyl}-carbamic acid tert-butyl ester 
• 154920-40-8 10-cyano-9-(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9-diazadecane 
• 154920-41-9 9,12-di(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9,12-triazododecane 
• 173406-25-2 [3-({2-[(2-Amino-ethyl)-benzyl-amino]-ethyl}-benzyl-amino)-propyl]-carbamic acid tert-butyl ester 
• 154920-42-0 13-cyano-9,12-di(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9,12-triazotridecane 
• 154920-43-1 9,12,15-tri(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9,12,15-tetraazapentadecane 
• 154920-44-2 16-cyano-9,12,15-tri(phenylmethyl)-2,2-dimethyl-3-oxa-4-oxo-5,9,12,15-tetraazahexadecane 
• 154920-49-7 (3-{[2-({2-[(2-Amino-ethyl)-benzyl-amino]-ethyl}-benzyl-amino)-ethyl]-benzyl-amino}-propyl)-carbamic acid tert-butyl ester 

Downstream Products

• 154920-46-4 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-6-O-(phenylmethyl)-N-<15-methyl-14-oxo-4,7,10,13-tetrakis(phenylmethyl)-4,7,10,13-tetraazahexadec-1-yl>-2'-deoxyguanosine 
• 154920-50-0 C₆₃H₉₁N₉O₆Si₂ 
• 154920-38-4 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-N-<4,7,10,13-tetrakis(phenylmethyl)-4,7,10,13-tetraazatridec-1-yl>-2'-deoxyguanosine 

Relevant articles and documents

Antisense modulation of MDM2 expression

Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Oligonucleotides containing N-2 substituted purines

This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.

Synthesis of 2'-deoxyguanosine containing a N2-polyamine

The synthesis of benzylated N2-(4,7,10,13-tetraazatridec-1-yl)-2'- deoxyguanosines 4 was accomplished by a key nucleophilic reaction of the novel unsymmetrical polyamine 2, with 3',5'-O-(tetraisopropyldisiloxane-1,3- diyl)-2-chloro-2'-deoxyinos